Ashley McEvoy - 23 Aug 2023 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WW Chair, MedTech
Signature
/s/ Raavi K. Deol, as attorney-in-fact for Ashley McEvoy
Issuer symbol
JNJ
Transactions as of
23 Aug 2023
Net transactions value
$0
Form type
4
Filing time
25 Aug 2023, 16:07:43 UTC
Previous filing
15 Feb 2023
Next filing
14 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Disposed to Issuer $0 -2,787 -5.1% $0.000000 52,038 23 Aug 2023 Direct F1, F2
holding JNJ Common Stock 2,806 23 Aug 2023 By 401k F3
holding JNJ Common Stock 300 23 Aug 2023 By ESOP F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock.
F2 On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
F3 Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
F4 Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).